Alfigen

The company has developed the AV411 product portfolio, which includes the lead drug compound in Phase II and proprietary analogs, representing a novel non-opioid for the treatment of various large pain and drug addiction indications. AV411 is an orally bioavailable small molecule; a glial cell attenuator that inhibits pro-inflammatory cytokines IL-1β, TNFα, and IL-6; and a functional antagonist of Toll-like receptor 4 (TLR4), which may contribute to its attenuation of neuroinflammation. AV411 is currently being evaluated in a Phase Ib/IIa clinical trial.